As HRSA's 340B Rebate Model Pilot moves toward its effective date, Valerie Bandy, PharmD, of Tecsys explains what drug-by-drug rebate tracking really demands from hospital and health system pharmacies.
Commentary|Podcasts|May 30, 2025
How Recent Executive Orders Impact the Drug Pricing Landscape
Author(s)Nicholas Saraceno, Senior Editor
Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.
Advertisement
In this exclusive PC Podcast interview, Alice Valder Curran, partner at Hogan Lovells, explores:
- How recent executive orders—both under the Biden and Trump administrations—have reshaped the drug pricing landscape, and the legal challenges or uncertainties they present for pharmaceutical companies
- What life sciences companies should be doing now to proactively prepare for further executive action on drug pricing and market access
- The key differences in how executive policies versus legislative actions affect the pharma industry’s pricing and commercialization strategies
- The legal and strategic risks executive policy shifts pose to investors and biopharma leaders who may be planning product launches or portfolio expansion over the next few years
The latest episode of The Pharmaceutical Commerce Podcast is available directly on
Advertisement
Related to this article
In this week's Pharma Pulse, DHL breaks ground on a new cold chain hub at Singapore's Changi Airport, a new report finds pharma's commercial model in the middle of a fundamental reset, and the FDA grants accelerated approval to sevabertinib.
In this week's Pharma Pulse, nine more drugmakers join the MFN program, GoodRx adds a family plan, IPC formalizes its USave partnership, and CSafe expands its thermal cover offerings.
Pharmacy directors are using the growing number of publicly visible drug prices as leverage, new research shows. Manufacturers need to be ready, before those prices become a negotiation tool.
As loss-of-exclusivity events accelerate, generics and biosimilars are diverging into distinct business models, demanding different regulatory, IP, and market access strategies from manufacturers.
Nine more manufacturers join the MFN program, pairing new Medicaid pricing deals with $19.6B in U.S. manufacturing investment and API reserve donations.
The White House said Medicaid programs in all 50 states, D.C. and Puerto Rico now receive MFN prices, with nearly $65 billion in savings over a decade.
Rebate delays could force 340B hospitals to pay upfront and wait months for credit, distorting drug spend on the books. Valerie Bandy, PharmD, of Tecsys explains the fallout.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Pharma Pulse: Independent Pharmacies Sue Express Scripts, Novo Taps Anthropic, Pharma Joins Clean Heat
2
White House Extends MFN Pricing to Every State Medicaid Program
3
The PBM Entity No Pharmaceutical Company Directly Contracted With
4
How Rebate Timing Distorts a Pharmacy's 340B Books
5